Dextran
Blood Substitutes and Plasma Protein Fractions
Sold as LMD 10% IN DEXTROSE 5% · LMD 10% IN 0.9% SODIUM…
- Drug class
- Blood Substitutes and Plasma Protein Fractions
- Availability
- Over-the-counter
- Routes
- Ophthalmic, Intravenous
- Markets covered
- 2
- Products on record
- 4
- FDA reports (12 mo)
- 137
Overview
Plain-language summary, compiled from the cited regulatory records
Dextran is a blood substitute and plasma protein fraction [1]. It is approved for use in relieving eye redness caused by minor irritations and as a lubricant to prevent further irritation or relieve eye dryness [1].
In the past 12 months, there have been 137 adverse event reports associated with dextran [2]. The most frequently reported reactions include off-label use, infusion-related reactions, dyspnoea, anaphylactic reactions, and flushing [2]. Dextran is available under various brand names [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 2 | April 29, 2026 |
| CA Canada | Health Canada | 2 | March 22, 2025 |
USUnited States· FDA
2 products
Uses
Uses • relieves redness of the eye due to minor eye irritations • as a lubricant to prevent further irritation or to relieve dryness of the eye
How to take
CACanada· Health Canada
2 products
2 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [2].
Drug interactions
Known interactions involving Dextran. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 011473a8-26d5-46… · revised April 29, 2026 [PDF]
- [2]Health Canada (DPD) · 00224227 · revised March 22, 2025
- [3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.